Get all premium features to the best stock analysis tool

Avantor® Reports Fourth Quarter and Full Year 2025 Results

Revival program underway, including relaunch of VWR brand, implementation of critical manufacturing and supply chain improvements, and upgrades to e-commerce channel Fourth Quarter 2025 Net sales of $1.66 billion, decrease of 1%; organic decrease of 4% Net income of $52 million; Adjusted EBITDA of $252 million Diluted GAAP EPS of $0.08; adjusted EPS of $0.22 Operating cash flow of $153 million; free cash flow of $117 million Full Year 2025 Net sales of $6.55 billion, decrease of 3%; organic decline of 3% Net loss of $530 million; Adjusted EBITDA of $1,069 million Diluted GAAP loss per share of $0.78; adjusted EPS of $0.90 Operating cash flow of $624 million; free cash flow of $496 million RADNOR, Pa., Feb. 11, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its fourth fiscal quarter and year ended December 31, 2025.

Kuehn Law Encourages Investors of Avantor, Inc. to Contact Law Firm

NEW YORK, Jan. 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Avantor, Inc. (NYSE: AVTR)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Insiders at Avantor caused the company to misrepresent or fail to disclose that: (1) Avantor's competitive positioning was weaker than had been publicly represented; (2) Avantor was experiencing negative effects from increased competition; and (3) as a result, representations about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

Kuehn Law Encourages Investors of Avantor, Inc. to Contact Law Firm

New York, New York--(Newsfile Corp. - January 15, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Avantor, Inc. (NYSE: AVTR) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Avantor caused the company to misrepresent or fail to disclose that: (1) Avantor's competitive positioning was weaker than had been publicly represented; (2) Avantor was experiencing negative effects from increased competition; and (3) as a result, representations about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

p-Chip Corporation, Choice One Rx, and RxERP Launch Precedent-Setting Trial Demonstrating Digital Traceability of Drug Supply Chains and Chain-of-Identity for DSCSA Compliance, Co-Sponsored by Avantor

CHICAGO--(BUSINESS WIRE)-- #Biotech--Trial will demonstrate advanced traceability of drugs for Oncology, Urology, Rheumatology and Gastroenterology across pharmaceutical supply chain.